source
- Oculis’ investigational eye drop OCS-01 fails Phase 3 trials for diabetic macular edema, shares tumbleOculis announced that its experimental eye drop OCS-01 did not meet primary endpoints in two Phase 3 studies aimed at treating diabetic macular edema. The trials were intended to evaluate the drug…
- Eli Lilly licenses Hanmi's GLP-2 asset for $75 million upfrontEli Lilly has signed a licensing agreement with South Korean biotech Hanmi to acquire rights to a GLP-2 drug candidate, paying an upfront cash payment of $75 million. The deal marks Lilly's entry…